Don't miss your chance to learn about #NIH_CFDE #data resources and a new platform for querying the Gene Expression Omnibus (GEO) with #gene sets! Tune in to this webinar on Fri 5/31 at 1PM ET. Learn more: https://t.co/J86rwCT6dQ

Now online from @me_lindholm and @DavidAm79279702 and colleagues of the #MoTrPAC consortium - explore the underlying data at https://t.co/bv0w4BhGmI and analysis R packages led by @nicolergay at

If you’re looking for the #MoTrPAC @Nature paper after exploring the data at https://t.co/bv0w4BhGmI here is the pdf link:

Explore the underlying data at

@NatMetabolism @CellGenomics @NatureComms To explore this data, go to https://t.co/eifPlq1GGZ. Here you can download data, look at how exercise regulates your favorite genes/proteins/metabolites across tissues or interactively compare training-induced tissue- and sex-specific enrichments in your tissues of interest. /n

The genetics of human performance https://t.co/3rFb2C3iwa #Review by @danseungkim, @MWheelerMD & @euanashley @StanCVFellows @StanfordDeptMed @Stanford Free to read here: https://t.co/FIaaFpVtEM #SharedIt

Moving day! #AcademicTwitter See you at https://t.co/itKe9Vprtb thanks for all the fish

So amazing to see this preprint out - incredible work by the entire #MoTrPAC team and especially co-leads @nicolergay @DavidAm79279702 @PierreMichelJ10! Thanks to @NIH_CommonFund for continuing support

All all data underlying https://t.co/ts2InNGUjW , including annotations of all human codons to @PfamDB-based evolutionary equivalent positions, are now available and ready to be plugged into your analysis pipeline. Available here: https://t.co/rVLM2nQvfQ

And of course huge thanks to the many patient participants here and elsewhere who have collectively volunteered years of their time to ensure data collected (including through the pandemic) continues to be high quality. 4/4

Importantly Mavacamten is first in class, with other sarcomere modulators in trials…we hope to learn more through clinical roll-out and PMA studies. Thanks to collaborators at MYOK and BMS. Thanks to Masataka Kawana and our clinical research team over the past 7 years…3/4

To determine safety & efficacy in patients with nonobstructive #HCM to assess if targeting the mechanistic origin of disease leads to alteration of long term disease progression, arrhythmia burden, hypertrophy… 2/4

Excited to see #mavacamten approval for patients with symptomatic obstructive hypertrophic cardiomyopathy! Spudich lab @stanford fundamental biophysics facilitating MyoKardia small molecule, trials @StanfordMed since 2015 - SAD, EXPLORER, VALOR, MAVA-LTE…more work to be done 1/4

Congrats to rising star @ADevareddyMD @StanfordMedRes for presenting our results analyzing progression of disease in the pre-#mavacamten era using serial CPET testing in #HCM patients @StanfordMed #ACC22 @euanashley @jwc14 @Ron_Witteles

Article Ideation by Artificial Intelligence vs Actual Individuals

Our featured article: The genetics of human performance https://t.co/3rFb2C3iwa #Review by @danseungkim, @MWheelerMD & @euanashley @StanCVFellows @StanfordDeptMed @Stanford Free to read here: https://t.co/FIaaFpVtEM #SharedIt

@euanashley @MWheelerMD @vnparikh @ChloeReuterCGC @juliaplatt And TOMORROW from 12-1pm Pacific Time, we will be welcoming pioneers in clinical cardiovascular genetics, Dr. Richard Bagnall, PhD and Professor Chris Semsarian, all the way from Australia! Register here: https://t.co/RsR51Tted7. @rdbagnall @CSHeartResearch

Who has #LongCovid? A #BigData approach https://t.co/1i8dFUFNm8 @ncats_nih_gov @data2health #EHR #TeamScience at unprecedented scale in #N3C!

Look forward to more data from the sponsors, academics and further trials in terms of in vivo genome scale edits across tissues

But we will have to see if there are any longer term unintended off target (both tissue and gene) effects that this prelim report don’t address. Reminder for TTR patients out there there are efficacious treatments approved and available, though cost is a real concern